权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

High Density Cell Respirator (HDCR) for the production of vectors, viruses and vaccines

用于生产载体、病毒和疫苗的高密度细胞呼吸器 (HDCR)

基本信息

批准号：
10011526
负责人：
Nicole Bergman
金额：
$ 25.02万
依托单位：
XDEMICS CORPORATION
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-01 至 2021-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10011526
关键词：
Architecture Blindness Businesses California Cell Adhesion Cell Culture Techniques Cell Density Cell Line Cell Therapy Cells Cellular immunotherapy Cities Clinical Clinical Treatment Clinical Trials Collaborations Communicable Diseases Data Defect Development Devices Disease Dose Event Excision Film Funding Future Gases Gene Transduction Agent Genes Genetic Engineering Genetic Medicine Genetic Vectors Goals Growth Harvest Immunologic Deficiency Syndromes Inborn Errors of Metabolism Industry Standard Injections Institutes Institution Investigation Joints Legal patent Life Liquid substance Malignant Neoplasms Mechanical Ventilators Mediating Medical center Medicine Membrane Methodology Methods Molds Names Nonprofit Organizations Nutrient Oncogenes Oncolytic Oncolytic viruses Orthopoxvirus Oxygen Patients Pattern Permeability Phase Phase I/II Trial Population Poxviridae Price Process Production Productivity Reagent Research Research Priority Savings Scientist Silicone Elastomers Small Business Innovation Research Grant Small Business Technology Transfer Research Societies Speed Suspensions Technology Testing Therapeutic Therapeutic Agents Thinness Time Vaccines Viral Viral Vaccines Viral Vector Virus Waiting Lists Work adeno-associated viral vector base cancer therapy cell growth cellular transduction clinically relevant cost cost effective density design engineered stem cells fighting gene therapy gene transfer vector hydrophilicity improved manufacturing process melanoma new technology novel novel therapeutics oncolytic virotherapy pandemic disease particle phase 1 study phase 2 study polydimethylsiloxane prototype research and development shear stress transmission process vector vector genome wasting

项目摘要

PROJECT SUMMARY/ABSTRACT This Phase I/II STTR Fast Track proposal responds to the call from the 2018/2019 NCATS SBIR/STTR Research Priorities to develop technologies so that “new treatments and cures for disease can be delivered to patients more quickly”. The production of life-altering gene editing vectors, cancer killing viruses, and life- saving vaccines currently depends on traditional cell culture techniques. A number of virus-based and cell- based therapies have become clinical treatments for cancer, for genetically-related blindness, for immunodeficiency, and for inborn errors of metabolism. In this exciting field, many therapies being developed are on waitlists to be tested. However, current cell culture-based production is costly and slow to attend the existing demand. For instance, a clinical trial for AAV-based gene editing requires 1016-17 viral particles, a quantity currently requiring a year for production and costing 1-2 million dollars. Thus, the cost of $400,000 to $1,400,000 per patient for recently approved gene medicines is not surprising. These price tags simply are not sustainable for society. In the event of a pandemic, it would take years to generate sufficient doses of vaccines to protect the 7 billion world population by current production methods. Thus, increasing the efficiency and speed of culture of production cell lines are common goals for manufacturing of gene editing vectors, oncolytic viruses, and vaccines. Our joint research efforts at XDemics Corporation, the California Institute of Technology, and the City of Hope National Medical Center, have resulted in an improved method of cell culture. Based on a known fact that oxygen delivery is the most rate-limiting process for increasing cell density, viability, and virus production we created a novel high density cell respirator (HDCR) (US Patent no. 10,053,660) from highly oxygen permeable material that can be inexpensively molded into large sheets, with integrated cell retention architecture, for efficient membrane oxygenation of adherent or suspension cells. Our hypothesis is that elimination of shear stress and the low flow media delivery through the HDCR, enabled by the decoupling of gas exchange via membrane oxygenation of cells, will allow for improved yield, decreased cost, and increased speed of production of therapeutic viral vectors and viruses. We have preliminary data confirming this hypothesis and have produced prototypes for optimization. Herein we propose Phase I studies to optimize the design of the HDCR for cell growth and demonstrate virus production. Proposed Phase II studies will consist of research and development of production processes for multiple viral vectors, including AAV and immuno- oncolytic poxvirus/vaccine. We expect that the HDCR will disrupt the field of vector and virus production, by allowing >10 times greater efficiency and >2-10 times greater speed of production. Our long-term goal is to speed up production of clinically-relevant quantities of viral medicines and vaccines from years down to months. Decreasing the cost of gene therapy vectors, cell-based immunotherapies, and vaccines will accelerate development of novel therapies for treating cancers, gene defects, and infectious diseases.

项目总结/文摘